These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23103817)

  • 21. [Immune molecules and the mechanism of joint destruction].
    Komatsu N
    Clin Calcium; 2016 May; 26(5):683-9. PubMed ID: 27117613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis.
    Lee EY; Lee ZH; Song YW
    Autoimmun Rev; 2013 Mar; 12(5):554-7. PubMed ID: 23092582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kirenol exerts a potent anti-arthritic effect in collagen-induced arthritis by modifying the T cells balance.
    Lu Y; Xiao J; Wu ZW; Wang ZM; Hu J; Fu HZ; Chen YY; Qian RQ
    Phytomedicine; 2012 Jul; 19(10):882-9. PubMed ID: 22673798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review: Immune cells and mediators of inflammatory arthritis.
    Schett G
    Autoimmunity; 2008 Apr; 41(3):224-9. PubMed ID: 18365836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis.
    Kwok SK; Cho ML; Park MK; Oh HJ; Park JS; Her YM; Lee SY; Youn J; Ju JH; Park KS; Kim SI; Kim HY; Park SH
    Arthritis Rheum; 2012 Mar; 64(3):740-51. PubMed ID: 21968544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
    Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
    Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone and joint destruction in rheumatoid arthritis: what is really happening?
    Goldring SR
    J Rheumatol Suppl; 2002 Sep; 65():44-8. PubMed ID: 12236623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
    Paleolog EM; Young S; Stark AC; McCloskey RV; Feldmann M; Maini RN
    Arthritis Rheum; 1998 Jul; 41(7):1258-65. PubMed ID: 9663484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoclasts in arthritis and Th17 cell development.
    Okamoto K; Takayanagi H
    Int Immunopharmacol; 2011 May; 11(5):543-8. PubMed ID: 21081190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular and molecular pathways of structural damage in rheumatoid arthritis.
    Harre U; Schett G
    Semin Immunopathol; 2017 Jun; 39(4):355-363. PubMed ID: 28597065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis.
    Koenders MI; Marijnissen RJ; Devesa I; Lubberts E; Joosten LA; Roth J; van Lent PL; van de Loo FA; van den Berg WB
    Arthritis Rheum; 2011 Aug; 63(8):2329-39. PubMed ID: 21520013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis.
    Matsui T; Nakata N; Nagai S; Nakatani A; Takahashi M; Momose T; Ohtomo K; Koyasu S
    J Nucl Med; 2009 Jun; 50(6):920-6. PubMed ID: 19443596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenesis of joint destruction in rheumatoid arthritis.
    Shiozawa S; Tsumiyama K; Yoshida K; Hashiramoto A
    Arch Immunol Ther Exp (Warsz); 2011 Apr; 59(2):89-95. PubMed ID: 21327737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis.
    Braun T; Zwerina J
    Arthritis Res Ther; 2011 Jul; 13(4):235. PubMed ID: 21861862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
    Kotake S; Sato K; Kim KJ; Takahashi N; Udagawa N; Nakamura I; Yamaguchi A; Kishimoto T; Suda T; Kashiwazaki S
    J Bone Miner Res; 1996 Jan; 11(1):88-95. PubMed ID: 8770701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis.
    Malemud CJ
    Clin Chim Acta; 2007 Jan; 375(1-2):10-9. PubMed ID: 16893535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Piascledine modulates the production of VEGF and TIMP-1 and reduces the invasiveness of rheumatoid arthritis synoviocytes.
    Cinelli M; Guiducci S; Del Rosso A; Pignone A; Del Rosso M; Fibbi G; Serratì S; Gabrielli A; Giacomelli R; Piccardi N; Matucci Cerinic M
    Scand J Rheumatol; 2006; 35(5):346-50. PubMed ID: 17062432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pathological mechanisms in rheumatoid arthritis].
    Tanaka Y
    Nihon Rinsho; 2013 Jul; 71(7):1147-52. PubMed ID: 23961659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Animal models for bone and joint disease. Osteoimmunology and animal models for rheumatoid arthritis].
    Komatsu N; Takayanagi H
    Clin Calcium; 2011 Feb; 21(2):269-76. PubMed ID: 21289424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.